AR069233A1 - Anticuerpos anti- factor b y sus usos - Google Patents

Anticuerpos anti- factor b y sus usos

Info

Publication number
AR069233A1
AR069233A1 ARP080104888A ARP080104888A AR069233A1 AR 069233 A1 AR069233 A1 AR 069233A1 AR P080104888 A ARP080104888 A AR P080104888A AR P080104888 A ARP080104888 A AR P080104888A AR 069233 A1 AR069233 A1 AR 069233A1
Authority
AR
Argentina
Prior art keywords
factor
complement
antibody
prevention
treatment
Prior art date
Application number
ARP080104888A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069233(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR069233A1 publication Critical patent/AR069233A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP080104888A 2007-11-08 2008-11-07 Anticuerpos anti- factor b y sus usos AR069233A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08

Publications (1)

Publication Number Publication Date
AR069233A1 true AR069233A1 (es) 2010-01-06

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104888A AR069233A1 (es) 2007-11-08 2008-11-07 Anticuerpos anti- factor b y sus usos

Country Status (15)

Country Link
US (4) US8158762B2 (cg-RX-API-DMAC7.html)
EP (1) EP2209807A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011503094A (cg-RX-API-DMAC7.html)
KR (1) KR20100105587A (cg-RX-API-DMAC7.html)
CN (1) CN101918444A (cg-RX-API-DMAC7.html)
AR (1) AR069233A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008323939A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820343A2 (cg-RX-API-DMAC7.html)
CA (1) CA2704973A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008003313A1 (cg-RX-API-DMAC7.html)
IL (1) IL205577A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010005115A (cg-RX-API-DMAC7.html)
PE (1) PE20091022A1 (cg-RX-API-DMAC7.html)
TW (1) TW200927170A (cg-RX-API-DMAC7.html)
WO (1) WO2009061910A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CN114890943A (zh) 2013-11-15 2022-08-12 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途
EA201892225A1 (ru) 2016-04-04 2019-09-30 БИОВЕРАТИВ ЮЭсЭй ИНК. АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
AU2021261257A1 (en) 2020-04-20 2022-12-22 Genzyme Corporation Humanized anti-complement factor Bb antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
EP2134173A4 (en) 2007-03-01 2010-11-10 Wellstat Ophthalmics Corp TREATMENT OF DISEASES SIGNED BY IGNITION

Also Published As

Publication number Publication date
US20180037667A1 (en) 2018-02-08
CL2008003313A1 (es) 2010-02-05
JP2011503094A (ja) 2011-01-27
WO2009061910A1 (en) 2009-05-14
PE20091022A1 (es) 2009-07-16
AU2008323939A1 (en) 2009-05-14
TW200927170A (en) 2009-07-01
CA2704973A1 (en) 2009-05-14
US20120230997A1 (en) 2012-09-13
US20090123469A1 (en) 2009-05-14
IL205577A0 (en) 2010-11-30
US20160024224A1 (en) 2016-01-28
US8158762B2 (en) 2012-04-17
EP2209807A1 (en) 2010-07-28
KR20100105587A (ko) 2010-09-29
CN101918444A (zh) 2010-12-15
MX2010005115A (es) 2010-05-27
BRPI0820343A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
CL2022000328A1 (es) Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017)
BRPI0811142A8 (pt) prevenção e tratamento de condições oculares associadas a complementos
AR069233A1 (es) Anticuerpos anti- factor b y sus usos
CL2019002470A1 (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
DOP2010000234A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
UY29392A1 (es) Metodos para el tratamiento de la angiogenesis ocular, el edema retinal, la isquemia retinal y la retinopatia diabetica mediante el uso de inhibidores selectivos de los receptores de la tirosinquinasa.
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
UY32819A (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2
MX2011008680A (es) Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR059213A1 (es) Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX380191B (es) Combinaciones de modalidades para el tratamiento de la diabetes.
WO2007038453A3 (en) Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
MX363822B (es) Formulaciones de liposomas.
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
JP2018532804A5 (cg-RX-API-DMAC7.html)
DE602006019948D1 (de) Koppelten rezeptors zur behandlung von makuladegeneration
AR079683A1 (es) Formulacion topica oftalmica de peptidos
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
WO2009089399A3 (en) Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular

Legal Events

Date Code Title Description
FA Abandonment or withdrawal